American Diabetes Association
Browse
Supplementary_Material(2).pdf (4.26 MB)

Inhibition of HSP20 ameliorates steatotic liver disease by stimulating ERK2-dependent autophagy

Download (4.26 MB)
figure
posted on 2024-03-11, 18:46 authored by Yanli Miao, Yi Zhong, Yutian Li, Haojie Qin, Ling Yang, Guojun Cao, Yong Tang, Ting Yu, Di Fan, Yang Lu, Jiangtong Peng, Kai Huang

Heat shock protein 20 (HSP20) emerges as a novel regulator of autophagy in the heart. Nonetheless, the detailed function of HSP20 in liver and its effect on autophagy remain unknown. Here, we observed that HSP20 expression is increased in liver tissues from mice and patients with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD). Liver-specific downregulation of HSP20 mitigates hepatic steatosis and insulin resistance in obese mice, while upregulating HSP20 promotes lipid deposition and hepatocyte cell death. Mechanistically, Liquid chromatography tandem mass spectrometry (LC-MS/MS) revealed that HSP20 interacts with phosphorylated extracellular regulated protein kinases 2 (ERK2) and prevents its dephosphorylation by dual specificity phosphatase 6 (DUSP6), leading to ERK2-mediated repression of autophagy, resulting in aggravated saturated fatty acid (SFA)-triggered hepatocyte death. Importantly, such adverse effects could be ameliorated by ERK inhibitor. Our data reveals a framework of how HSP20 increases susceptibility of SFA-induced liver injury through enhancing ERK2 phosphorylation, which represents a plausible therapeutic intervention to combat MASLD.

Funding

This work has been supported by grants from National Natural Science Foundation of China (81900519, 81900257, 91949201 and 81830014).

History

Usage metrics

    Diabetes

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC